#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	ana	3-1

#Text=It is believed that an ideal vaccine against Leishmania spp .
3-1	14-16	It	abstract	giv	_	_
3-2	17-19	is	_	_	_	_
3-3	20-28	believed	_	_	_	_
3-4	29-33	that	_	_	_	_
3-5	34-36	an	substance[3]	new[3]	_	_
3-6	37-42	ideal	substance[3]	new[3]	_	_
3-7	43-50	vaccine	substance[3]	new[3]	_	_
3-8	51-58	against	substance[3]	new[3]	_	_
3-9	59-69	Leishmania	substance[3]|abstract	new[3]|new	coref	6-27
3-10	70-73	spp	substance[3]	new[3]	_	_
3-11	74-75	.	_	_	_	_

#Text=should have epitopes that will be recognized by APCs and will be able to trigger a T- lymphocyte effector response and maintain a long-lasting immune memory , which would be critical for protection against the parasite .
4-1	76-82	should	_	_	_	_
4-2	83-87	have	_	_	_	_
4-3	88-96	epitopes	object	new	coref	5-7[15_0]
4-4	97-101	that	_	_	_	_
4-5	102-106	will	_	_	_	_
4-6	107-109	be	_	_	_	_
4-7	110-120	recognized	_	_	_	_
4-8	121-123	by	_	_	_	_
4-9	124-128	APCs	abstract	new	_	_
4-10	129-132	and	_	_	_	_
4-11	133-137	will	_	_	_	_
4-12	138-140	be	_	_	_	_
4-13	141-145	able	_	_	_	_
4-14	146-148	to	_	_	_	_
4-15	149-156	trigger	_	_	_	_
4-16	157-158	a	event[9]	new[9]	coref	21-35[167_9]
4-17	159-161	T-	event[9]	new[9]	_	_
4-18	162-172	lymphocyte	person|event[9]	new|new[9]	_	_
4-19	173-181	effector	person|event[9]	new|new[9]	_	_
4-20	182-190	response	event[9]	new[9]	_	_
4-21	191-194	and	_	_	_	_
4-22	195-203	maintain	_	_	_	_
4-23	204-205	a	abstract[11]	new[11]	coref	23-26[181_11]
4-24	206-218	long-lasting	abstract[11]	new[11]	_	_
4-25	219-225	immune	abstract|abstract[11]	new|new[11]	_	_
4-26	226-232	memory	abstract[11]	new[11]	_	_
4-27	233-234	,	_	_	_	_
4-28	235-240	which	_	_	_	_
4-29	241-246	would	_	_	_	_
4-30	247-249	be	_	_	_	_
4-31	250-258	critical	_	_	_	_
4-32	259-262	for	_	_	_	_
4-33	263-273	protection	abstract[12]	new[12]	coref	16-11[0_12]
4-34	274-281	against	abstract[12]	new[12]	_	_
4-35	282-285	the	abstract[12]|person[13]	new[12]|new[13]	_	_
4-36	286-294	parasite	abstract[12]|person[13]	new[12]|new[13]	_	_
4-37	295-296	.	_	_	_	_

#Text=Therefore , the high-throughput search for epitopes with this potential has become one of the greatest current challenges for the rational design of vaccines .
5-1	297-306	Therefore	_	_	_	_
5-2	307-308	,	_	_	_	_
5-3	309-312	the	abstract[14]	new[14]	_	_
5-4	313-328	high-throughput	abstract[14]	new[14]	_	_
5-5	329-335	search	abstract[14]	new[14]	_	_
5-6	336-339	for	abstract[14]	new[14]	_	_
5-7	340-348	epitopes	abstract[14]|object[15]	new[14]|giv[15]	coref	6-23[26_15]
5-8	349-353	with	abstract[14]|object[15]	new[14]|giv[15]	_	_
5-9	354-358	this	abstract[14]|object[15]|abstract[16]	new[14]|giv[15]|new[16]	_	_
5-10	359-368	potential	abstract[14]|object[15]|abstract[16]	new[14]|giv[15]|new[16]	_	_
5-11	369-372	has	_	_	_	_
5-12	373-379	become	_	_	_	_
5-13	380-383	one	object[17]	new[17]	_	_
5-14	384-386	of	object[17]	new[17]	_	_
5-15	387-390	the	object[17]|abstract[18]	new[17]|new[18]	_	_
5-16	391-399	greatest	object[17]|abstract[18]	new[17]|new[18]	_	_
5-17	400-407	current	object[17]|abstract[18]	new[17]|new[18]	_	_
5-18	408-418	challenges	object[17]|abstract[18]	new[17]|new[18]	_	_
5-19	419-422	for	object[17]|abstract[18]	new[17]|new[18]	_	_
5-20	423-426	the	object[17]|abstract[18]|abstract[19]	new[17]|new[18]|new[19]	_	_
5-21	427-435	rational	object[17]|abstract[18]|abstract[19]	new[17]|new[18]|new[19]	_	_
5-22	436-442	design	object[17]|abstract[18]|abstract[19]	new[17]|new[18]|new[19]	_	_
5-23	443-445	of	object[17]|abstract[18]|abstract[19]	new[17]|new[18]|new[19]	_	_
5-24	446-454	vaccines	object[17]|abstract[18]|abstract[19]|substance	new[17]|new[18]|new[19]|new	coref	21-31
5-25	455-456	.	_	_	_	_

#Text=Thus , reverse vaccinology started to be used for this purpose , and one of the strategies used is the search for immunogenic epitopes in whole Leishmania proteomes .
6-1	457-461	Thus	_	_	_	_
6-2	462-463	,	_	_	_	_
6-3	464-471	reverse	abstract[21]	new[21]	_	_
6-4	472-483	vaccinology	abstract[21]	new[21]	_	_
6-5	484-491	started	_	_	_	_
6-6	492-494	to	_	_	_	_
6-7	495-497	be	_	_	_	_
6-8	498-502	used	_	_	_	_
6-9	503-506	for	_	_	_	_
6-10	507-511	this	abstract[22]	new[22]	coref	15-9[105_22]
6-11	512-519	purpose	abstract[22]	new[22]	_	_
6-12	520-521	,	_	_	_	_
6-13	522-525	and	_	_	_	_
6-14	526-529	one	abstract[23]	new[23]	coref	6-20[25_23]
6-15	530-532	of	abstract[23]	new[23]	_	_
6-16	533-536	the	abstract[23]|abstract[24]	new[23]|new[24]	_	_
6-17	537-547	strategies	abstract[23]|abstract[24]	new[23]|new[24]	_	_
6-18	548-552	used	_	_	_	_
6-19	553-555	is	_	_	_	_
6-20	556-559	the	abstract[25]	giv[25]	_	_
6-21	560-566	search	abstract[25]	giv[25]	_	_
6-22	567-570	for	abstract[25]	giv[25]	_	_
6-23	571-582	immunogenic	abstract[25]|object[26]	giv[25]|giv[26]	coref	7-15[34_26]
6-24	583-591	epitopes	abstract[25]|object[26]	giv[25]|giv[26]	_	_
6-25	592-594	in	abstract[25]|object[26]	giv[25]|giv[26]	_	_
6-26	595-600	whole	abstract[25]|object[26]|object[28]	giv[25]|giv[26]|new[28]	coref	7-4[31_28]
6-27	601-611	Leishmania	abstract[25]|object[26]|place|object[28]	giv[25]|giv[26]|giv|new[28]	coref	24-15
6-28	612-621	proteomes	abstract[25]|object[26]|object[28]	giv[25]|giv[26]|new[28]	_	_
6-29	622-623	.	_	_	_	_

#Text=Epitope mapping in proteomes of parasites is much more complex than the mapping of epitopes in proteins already described as immunogenic .
7-1	624-631	Epitope	abstract|abstract[30]	new|new[30]	coref	24-5
7-2	632-639	mapping	abstract[30]	new[30]	_	_
7-3	640-642	in	abstract[30]	new[30]	_	_
7-4	643-652	proteomes	abstract[30]|object[31]	new[30]|giv[31]	_	_
7-5	653-655	of	abstract[30]|object[31]	new[30]|giv[31]	_	_
7-6	656-665	parasites	abstract[30]|object[31]|animal	new[30]|giv[31]|new	coref	25-11[203_0]
7-7	666-668	is	_	_	_	_
7-8	669-673	much	_	_	_	_
7-9	674-678	more	_	_	_	_
7-10	679-686	complex	_	_	_	_
7-11	687-691	than	_	_	_	_
7-12	692-695	the	abstract[33]	new[33]	_	_
7-13	696-703	mapping	abstract[33]	new[33]	_	_
7-14	704-706	of	abstract[33]	new[33]	_	_
7-15	707-715	epitopes	abstract[33]|object[34]	new[33]|giv[34]	coref	8-32[47_34]
7-16	716-718	in	abstract[33]|object[34]	new[33]|giv[34]	_	_
7-17	719-727	proteins	abstract[33]|object[34]|substance	new[33]|giv[34]|new	_	_
7-18	728-735	already	_	_	_	_
7-19	736-745	described	_	_	_	_
7-20	746-748	as	_	_	_	_
7-21	749-760	immunogenic	_	_	_	_
7-22	761-762	.	_	_	_	_

#Text=In this way , the use of the integrative approach to immunoinformatics proposed by Brito , Guimaraes , Velloso , Correa-Oliveira , Ruiz , Reis and Resende was important to achieve potential epitopes in this study .
8-1	763-765	In	_	_	_	_
8-2	766-770	this	abstract[36]	new[36]	coref	26-2[206_36]
8-3	771-774	way	abstract[36]	new[36]	_	_
8-4	775-776	,	_	_	_	_
8-5	777-780	the	abstract[37]	new[37]	_	_
8-6	781-784	use	abstract[37]	new[37]	_	_
8-7	785-787	of	abstract[37]	new[37]	_	_
8-8	788-791	the	abstract[37]|abstract[38]	new[37]|new[38]	coref	22-5[170_38]
8-9	792-803	integrative	abstract[37]|abstract[38]	new[37]|new[38]	_	_
8-10	804-812	approach	abstract[37]|abstract[38]	new[37]|new[38]	_	_
8-11	813-815	to	abstract[37]|abstract[38]	new[37]|new[38]	_	_
8-12	816-833	immunoinformatics	abstract[37]|abstract[38]|abstract	new[37]|new[38]|new	coref	9-4
8-13	834-842	proposed	_	_	_	_
8-14	843-845	by	_	_	_	_
8-15	846-851	Brito	person	new	_	_
8-16	852-853	,	_	_	_	_
8-17	854-863	Guimaraes	person	new	_	_
8-18	864-865	,	_	_	_	_
8-19	866-873	Velloso	person	new	_	_
8-20	874-875	,	_	_	_	_
8-21	876-891	Correa-Oliveira	person	new	_	_
8-22	892-893	,	_	_	_	_
8-23	894-898	Ruiz	person	new	_	_
8-24	899-900	,	_	_	_	_
8-25	901-905	Reis	person	new	coref	14-3
8-26	906-909	and	_	_	_	_
8-27	910-917	Resende	person	new	_	_
8-28	918-921	was	_	_	_	_
8-29	922-931	important	_	_	_	_
8-30	932-934	to	_	_	_	_
8-31	935-942	achieve	_	_	_	_
8-32	943-952	potential	object[47]	giv[47]	coref	9-14[55_47]
8-33	953-961	epitopes	object[47]	giv[47]	_	_
8-34	962-964	in	object[47]	giv[47]	_	_
8-35	965-969	this	object[47]|object[48]	giv[47]|new[48]	_	_
8-36	970-975	study	object[47]|object[48]	giv[47]|new[48]	_	_
8-37	976-977	.	_	_	_	_

#Text=After employing the immunoinformatics methodologies , we identified MHC class I and class II ligand epitopes comprising mouse and human alleles , due to the absence of predictors comprising dog alleles .
9-1	978-983	After	_	_	_	_
9-2	984-993	employing	_	_	_	_
9-3	994-997	the	abstract[50]	new[50]	_	_
9-4	998-1015	immunoinformatics	abstract|abstract[50]	giv|new[50]	_	_
9-5	1016-1029	methodologies	abstract[50]	new[50]	_	_
9-6	1030-1031	,	_	_	_	_
9-7	1032-1034	we	person	acc	ana	10-8
9-8	1035-1045	identified	_	_	_	_
9-9	1046-1049	MHC	abstract|abstract[53]	new|new[53]	coref	10-19
9-10	1050-1055	class	abstract[53]	new[53]	_	_
9-11	1056-1057	I	person	acc	_	_
9-12	1058-1061	and	_	_	_	_
9-13	1062-1067	class	_	_	_	_
9-14	1068-1070	II	object[55]	giv[55]	coref	15-14[106_55]
9-15	1071-1077	ligand	object[55]	giv[55]	_	_
9-16	1078-1086	epitopes	object[55]	giv[55]	_	_
9-17	1087-1097	comprising	_	_	_	_
9-18	1098-1103	mouse	animal	new	_	_
9-19	1104-1107	and	_	_	_	_
9-20	1108-1113	human	abstract[57]	new[57]	coref	9-30[61_57]
9-21	1114-1121	alleles	abstract[57]	new[57]	_	_
9-22	1122-1123	,	abstract[57]	new[57]	_	_
9-23	1124-1127	due	abstract[57]	new[57]	_	_
9-24	1128-1130	to	_	_	_	_
9-25	1131-1134	the	abstract[58]	new[58]	_	_
9-26	1135-1142	absence	abstract[58]	new[58]	_	_
9-27	1143-1145	of	abstract[58]	new[58]	_	_
9-28	1146-1156	predictors	abstract[58]|abstract	new[58]|new	_	_
9-29	1157-1167	comprising	_	_	_	_
9-30	1168-1171	dog	animal|abstract[61]	new|giv[61]	coref	10-19[67_61]
9-31	1172-1179	alleles	abstract[61]	giv[61]	_	_
9-32	1180-1181	.	_	_	_	_

#Text=However , based on some studies , we can verify that there are high levels of identity between MHC alleles of dogs and those of humans and mice .
10-1	1182-1189	However	_	_	_	_
10-2	1190-1191	,	_	_	_	_
10-3	1192-1197	based	_	_	_	_
10-4	1198-1200	on	_	_	_	_
10-5	1201-1205	some	abstract[62]	new[62]	coref	13-1[88_62]
10-6	1206-1213	studies	abstract[62]	new[62]	_	_
10-7	1214-1215	,	_	_	_	_
10-8	1216-1218	we	person	giv	ana	12-15
10-9	1219-1222	can	_	_	_	_
10-10	1223-1229	verify	_	_	_	_
10-11	1230-1234	that	_	_	_	_
10-12	1235-1240	there	_	_	_	_
10-13	1241-1244	are	_	_	_	_
10-14	1245-1249	high	abstract[64]	new[64]	_	_
10-15	1250-1256	levels	abstract[64]	new[64]	_	_
10-16	1257-1259	of	abstract[64]	new[64]	_	_
10-17	1260-1268	identity	abstract[64]|abstract[65]	new[64]|new[65]	coref	11-14[75_65]
10-18	1269-1276	between	abstract[64]|abstract[65]	new[64]|new[65]	_	_
10-19	1277-1280	MHC	abstract[64]|abstract[65]|abstract|abstract[67]	new[64]|new[65]|giv|giv[67]	coref	11-8
10-20	1281-1288	alleles	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-21	1289-1291	of	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-22	1292-1296	dogs	abstract[64]|abstract[65]|abstract[67]|animal	new[64]|new[65]|giv[67]|new	coref	11-12
10-23	1297-1300	and	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-24	1301-1306	those	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-25	1307-1309	of	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-26	1310-1316	humans	abstract[64]|abstract[65]|abstract[67]|person	new[64]|new[65]|giv[67]|new	coref	11-19
10-27	1317-1320	and	abstract[64]|abstract[65]|abstract[67]	new[64]|new[65]|giv[67]	_	_
10-28	1321-1325	mice	abstract[64]|abstract[65]|abstract[67]|animal	new[64]|new[65]|giv[67]|new	coref	11-21
10-29	1326-1327	.	_	_	_	_

#Text=For example , some loci of the MHC region II of dogs have an identity with those of humans and mice around 85 % and 79 % , respectively .
11-1	1328-1331	For	_	_	_	_
11-2	1332-1339	example	_	_	_	_
11-3	1340-1341	,	_	_	_	_
11-4	1342-1346	some	abstract[71]	new[71]	_	_
11-5	1347-1351	loci	abstract[71]	new[71]	_	_
11-6	1352-1354	of	abstract[71]	new[71]	_	_
11-7	1355-1358	the	abstract[71]|abstract[73]	new[71]|new[73]	_	_
11-8	1359-1362	MHC	abstract[71]|place|abstract[73]	new[71]|giv|new[73]	_	_
11-9	1363-1369	region	abstract[71]|abstract[73]	new[71]|new[73]	_	_
11-10	1370-1372	II	abstract[71]|abstract[73]	new[71]|new[73]	_	_
11-11	1373-1375	of	abstract[71]|abstract[73]	new[71]|new[73]	_	_
11-12	1376-1380	dogs	abstract[71]|abstract[73]|animal	new[71]|new[73]|giv	coref	12-17[85_0]
11-13	1381-1385	have	_	_	_	_
11-14	1386-1388	an	abstract[75]	giv[75]	_	_
11-15	1389-1397	identity	abstract[75]	giv[75]	_	_
11-16	1398-1402	with	abstract[75]	giv[75]	_	_
11-17	1403-1408	those	abstract[75]	giv[75]	_	_
11-18	1409-1411	of	abstract[75]	giv[75]	_	_
11-19	1412-1418	humans	abstract[75]|person	giv[75]|giv	coref	13-8[90_0]
11-20	1419-1422	and	abstract[75]	giv[75]	_	_
11-21	1423-1427	mice	abstract[75]|animal	giv[75]|giv	_	_
11-22	1428-1434	around	abstract[75]|quantity[78]	giv[75]|new[78]	_	_
11-23	1435-1437	85	abstract[75]|quantity[78]	giv[75]|new[78]	_	_
11-24	1438-1439	%	abstract[75]|quantity[78]	giv[75]|new[78]	_	_
11-25	1440-1443	and	abstract[75]	giv[75]	_	_
11-26	1444-1446	79	abstract[75]|quantity[79]	giv[75]|new[79]	_	_
11-27	1447-1448	%	abstract[75]|quantity[79]	giv[75]|new[79]	_	_
11-28	1449-1450	,	_	_	_	_
11-29	1451-1463	respectively	_	_	_	_
11-30	1464-1465	.	_	_	_	_

#Text=Regarding the in vivo screening of the immunoinformatics-selected peptides in the canine model , we selected asymptomatic dogs naturally infected by L. infantum ( natural reservoir ) .
12-1	1466-1475	Regarding	_	_	_	_
12-2	1476-1479	the	abstract[80]	new[80]	coref	15-4[104_80]
12-3	1480-1482	in	abstract[80]	new[80]	_	_
12-4	1483-1487	vivo	abstract[80]	new[80]	_	_
12-5	1488-1497	screening	abstract[80]	new[80]	_	_
12-6	1498-1500	of	abstract[80]	new[80]	_	_
12-7	1501-1504	the	abstract[80]|substance[81]	new[80]|new[81]	coref	15-21[0_81]
12-8	1505-1531	immunoinformatics-selected	abstract[80]|substance[81]	new[80]|new[81]	_	_
12-9	1532-1540	peptides	abstract[80]|substance[81]	new[80]|new[81]	_	_
12-10	1541-1543	in	abstract[80]|substance[81]	new[80]|new[81]	_	_
12-11	1544-1547	the	abstract[80]|substance[81]|abstract[83]	new[80]|new[81]|new[83]	coref	20-12[150_83]
12-12	1548-1554	canine	abstract[80]|substance[81]|animal|abstract[83]	new[80]|new[81]|new|new[83]	_	_
12-13	1555-1560	model	abstract[80]|substance[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
12-14	1561-1562	,	_	_	_	_
12-15	1563-1565	we	person	giv	ana	15-2
12-16	1566-1574	selected	_	_	_	_
12-17	1575-1587	asymptomatic	animal[85]	giv[85]	coref	13-6[89_85]
12-18	1588-1592	dogs	animal[85]	giv[85]	_	_
12-19	1593-1602	naturally	_	_	_	_
12-20	1603-1611	infected	_	_	_	_
12-21	1612-1614	by	_	_	_	_
12-22	1615-1617	L.	person	new	_	_
12-23	1618-1626	infantum	_	_	_	_
12-24	1627-1628	(	_	_	_	_
12-25	1629-1636	natural	place[87]	new[87]	_	_
12-26	1637-1646	reservoir	place[87]	new[87]	_	_
12-27	1647-1648	)	_	_	_	_
12-28	1649-1650	.	_	_	_	_

#Text=Several studies have shown that dogs and humans with asymptomatic clinical forms have better reactivity with intra-dermal reaction than symptomatic individuals .
13-1	1651-1658	Several	abstract[88]	giv[88]	coref	20-6[147_88]
13-2	1659-1666	studies	abstract[88]	giv[88]	_	_
13-3	1667-1671	have	_	_	_	_
13-4	1672-1677	shown	_	_	_	_
13-5	1678-1682	that	_	_	_	_
13-6	1683-1687	dogs	animal[89]	giv[89]	coref	14-11[96_89]
13-7	1688-1691	and	animal[89]	giv[89]	_	_
13-8	1692-1698	humans	animal[89]|person[90]	giv[89]|giv[90]	_	_
13-9	1699-1703	with	animal[89]|person[90]	giv[89]|giv[90]	_	_
13-10	1704-1716	asymptomatic	animal[89]|person[90]|abstract[91]	giv[89]|giv[90]|new[91]	_	_
13-11	1717-1725	clinical	animal[89]|person[90]|abstract[91]	giv[89]|giv[90]|new[91]	_	_
13-12	1726-1731	forms	animal[89]|person[90]|abstract[91]	giv[89]|giv[90]|new[91]	_	_
13-13	1732-1736	have	_	_	_	_
13-14	1737-1743	better	abstract[92]	new[92]	_	_
13-15	1744-1754	reactivity	abstract[92]	new[92]	_	_
13-16	1755-1759	with	abstract[92]	new[92]	_	_
13-17	1760-1772	intra-dermal	abstract[92]|event[93]	new[92]|new[93]	_	_
13-18	1773-1781	reaction	abstract[92]|event[93]	new[92]|new[93]	_	_
13-19	1782-1786	than	abstract[92]|event[93]	new[92]|new[93]	_	_
13-20	1787-1798	symptomatic	abstract[92]|event[93]|person[94]	new[92]|new[93]|new[94]	_	_
13-21	1799-1810	individuals	abstract[92]|event[93]|person[94]	new[92]|new[93]|new[94]	_	_
13-22	1811-1812	.	_	_	_	_

#Text=Similarly , Reis , et al. have already shown that asymptomatic dogs have a profile of circulating lymphocytes in the peripheral blood capable of conferring a degree of resistance to the disease .
14-1	1813-1822	Similarly	_	_	_	_
14-2	1823-1824	,	_	_	_	_
14-3	1825-1829	Reis	person	giv	_	_
14-4	1830-1831	,	_	_	_	_
14-5	1832-1834	et	_	_	_	_
14-6	1835-1838	al.	_	_	_	_
14-7	1839-1843	have	_	_	_	_
14-8	1844-1851	already	_	_	_	_
14-9	1852-1857	shown	_	_	_	_
14-10	1858-1862	that	_	_	_	_
14-11	1863-1875	asymptomatic	animal[96]	giv[96]	_	_
14-12	1876-1880	dogs	animal[96]	giv[96]	_	_
14-13	1881-1885	have	_	_	_	_
14-14	1886-1887	a	object[97]	new[97]	_	_
14-15	1888-1895	profile	object[97]	new[97]	_	_
14-16	1896-1898	of	_	_	_	_
14-17	1899-1910	circulating	_	_	_	_
14-18	1911-1922	lymphocytes	substance[98]	new[98]	_	_
14-19	1923-1925	in	substance[98]	new[98]	_	_
14-20	1926-1929	the	substance[98]|object[99]	new[98]|new[99]	_	_
14-21	1930-1940	peripheral	substance[98]|object[99]	new[98]|new[99]	_	_
14-22	1941-1946	blood	substance[98]|object[99]	new[98]|new[99]	_	_
14-23	1947-1954	capable	_	_	_	_
14-24	1955-1957	of	_	_	_	_
14-25	1958-1968	conferring	_	_	_	_
14-26	1969-1970	a	abstract[100]	new[100]	_	_
14-27	1971-1977	degree	abstract[100]	new[100]	_	_
14-28	1978-1980	of	abstract[100]	new[100]	_	_
14-29	1981-1991	resistance	abstract[100]|abstract[101]	new[100]|new[101]	coref	18-10[0_101]
14-30	1992-1994	to	abstract[100]|abstract[101]	new[100]|new[101]	_	_
14-31	1995-1998	the	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|new[102]	_	_
14-32	1999-2006	disease	abstract[100]|abstract[101]|abstract[102]	new[100]|new[101]|new[102]	_	_
14-33	2007-2008	.	_	_	_	_

#Text=When we performed the in vitro screening , the purpose was to identify potential epitopes in a huge number of peptides .
15-1	2009-2013	When	_	_	_	_
15-2	2014-2016	we	person	giv	ana	16-4
15-3	2017-2026	performed	_	_	_	_
15-4	2027-2030	the	abstract[104]	giv[104]	coref	21-2[158_104]
15-5	2031-2033	in	abstract[104]	giv[104]	_	_
15-6	2034-2039	vitro	abstract[104]	giv[104]	_	_
15-7	2040-2049	screening	abstract[104]	giv[104]	_	_
15-8	2050-2051	,	_	_	_	_
15-9	2052-2055	the	abstract[105]	giv[105]	_	_
15-10	2056-2063	purpose	abstract[105]	giv[105]	_	_
15-11	2064-2067	was	_	_	_	_
15-12	2068-2070	to	_	_	_	_
15-13	2071-2079	identify	_	_	_	_
15-14	2080-2089	potential	object[106]	giv[106]	_	_
15-15	2090-2098	epitopes	object[106]	giv[106]	_	_
15-16	2099-2101	in	_	_	_	_
15-17	2102-2103	a	object[107]	new[107]	_	_
15-18	2104-2108	huge	object[107]	new[107]	_	_
15-19	2109-2115	number	object[107]	new[107]	_	_
15-20	2116-2118	of	object[107]	new[107]	_	_
15-21	2119-2127	peptides	object[107]|substance	new[107]|giv	coref	19-5[141_0]
15-22	2128-2129	.	_	_	_	_

#Text=For this , we focused on the main biomarkers of protection , namely : lymphocyte proliferation after stimulation with L. infantum and IFN-γ production by subpopulations of T-lymphocytes ( CD4+ and CD8+ ) .
16-1	2130-2133	For	_	_	_	_
16-2	2134-2138	this	_	_	_	_
16-3	2139-2140	,	_	_	_	_
16-4	2141-2143	we	person	giv	ana	18-4
16-5	2144-2151	focused	_	_	_	_
16-6	2152-2154	on	_	_	_	_
16-7	2155-2158	the	abstract[110]	new[110]	appos	16-13[113_110]
16-8	2159-2163	main	abstract[110]	new[110]	_	_
16-9	2164-2174	biomarkers	abstract[110]	new[110]	_	_
16-10	2175-2177	of	abstract[110]	new[110]	_	_
16-11	2178-2188	protection	abstract[110]|abstract	new[110]|giv	coref	17-7
16-12	2189-2190	,	_	_	_	_
16-13	2191-2197	namely	abstract[113]	giv[113]	coref	18-1[131_113]
16-14	2198-2199	:	abstract[113]	giv[113]	_	_
16-15	2200-2210	lymphocyte	abstract|abstract[113]	new|giv[113]	_	_
16-16	2211-2224	proliferation	abstract[113]	giv[113]	_	_
16-17	2225-2230	after	abstract[113]	giv[113]	_	_
16-18	2231-2242	stimulation	abstract[113]|event[114]	giv[113]|new[114]	_	_
16-19	2243-2247	with	abstract[113]|event[114]	giv[113]|new[114]	_	_
16-20	2248-2250	L.	abstract[113]|event[114]	giv[113]|new[114]	_	_
16-21	2251-2259	infantum	abstract[113]|event[114]	giv[113]|new[114]	_	_
16-22	2260-2263	and	abstract[113]|event[114]	giv[113]|new[114]	_	_
16-23	2264-2269	IFN-γ	abstract[113]|event[114]|object|abstract[116]	giv[113]|new[114]|new|new[116]	coref|coref	17-17[123_116]|19-16[144_0]
16-24	2270-2280	production	abstract[113]|event[114]|abstract[116]	giv[113]|new[114]|new[116]	_	_
16-25	2281-2283	by	_	_	_	_
16-26	2284-2298	subpopulations	object[117]	new[117]	_	_
16-27	2299-2301	of	object[117]	new[117]	_	_
16-28	2302-2315	T-lymphocytes	object[117]|abstract	new[117]|new	appos	16-30[119_0]
16-29	2316-2317	(	_	_	_	_
16-30	2318-2322	CD4+	abstract[119]	giv[119]	coref	17-27[128_119]
16-31	2323-2326	and	abstract[119]	giv[119]	_	_
16-32	2327-2331	CD8+	abstract[119]	giv[119]	_	_
16-33	2332-2333	)	_	_	_	_
16-34	2334-2335	.	_	_	_	_

#Text=Currently , some markers related to protection have been studied , such as proinflammatory cytokines , production of immunoglobulins of IgG1 and IgG2 subtypes , and responsive CD4+ and CD8+ T-cells .
17-1	2336-2345	Currently	_	_	_	_
17-2	2346-2347	,	_	_	_	_
17-3	2348-2352	some	abstract[120]	new[120]	_	_
17-4	2353-2360	markers	abstract[120]	new[120]	_	_
17-5	2361-2368	related	_	_	_	_
17-6	2369-2371	to	_	_	_	_
17-7	2372-2382	protection	abstract	giv	coref	25-17[204_0]
17-8	2383-2387	have	_	_	_	_
17-9	2388-2392	been	_	_	_	_
17-10	2393-2400	studied	_	_	_	_
17-11	2401-2402	,	_	_	_	_
17-12	2403-2407	such	_	_	_	_
17-13	2408-2410	as	_	_	_	_
17-14	2411-2426	proinflammatory	abstract[122]	new[122]	coref	23-34[183_122]
17-15	2427-2436	cytokines	abstract[122]	new[122]	_	_
17-16	2437-2438	,	_	_	_	_
17-17	2439-2449	production	abstract[123]	giv[123]	_	_
17-18	2450-2452	of	abstract[123]	giv[123]	_	_
17-19	2453-2468	immunoglobulins	abstract[123]|object[124]	giv[123]|new[124]	_	_
17-20	2469-2471	of	abstract[123]|object[124]	giv[123]|new[124]	_	_
17-21	2472-2476	IgG1	abstract[123]|object[124]|object	giv[123]|new[124]|new	_	_
17-22	2477-2480	and	abstract[123]|object[124]	giv[123]|new[124]	_	_
17-23	2481-2485	IgG2	abstract[123]|object[124]|abstract|abstract[127]	giv[123]|new[124]|new|new[127]	_	_
17-24	2486-2494	subtypes	abstract[123]|object[124]|abstract[127]	giv[123]|new[124]|new[127]	_	_
17-25	2495-2496	,	_	_	_	_
17-26	2497-2500	and	_	_	_	_
17-27	2501-2511	responsive	abstract[128]	giv[128]	coref	17-30[0_128]
17-28	2512-2516	CD4+	abstract[128]	giv[128]	_	_
17-29	2517-2520	and	_	_	_	_
17-30	2521-2525	CD8+	abstract|abstract[130]	giv|new[130]	coref	19-18[145_130]
17-31	2526-2533	T-cells	abstract[130]	new[130]	_	_
17-32	2534-2535	.	_	_	_	_

#Text=The biomarkers that we chose are essential to determine resistance or susceptibility to visceral leishmaniasis and they are widely demonstrated in the literature .
18-1	2536-2539	The	abstract[131]	giv[131]	_	_
18-2	2540-2550	biomarkers	abstract[131]	giv[131]	_	_
18-3	2551-2555	that	_	_	_	_
18-4	2556-2558	we	person	giv	ana	19-1
18-5	2559-2564	chose	_	_	_	_
18-6	2565-2568	are	_	_	_	_
18-7	2569-2578	essential	_	_	_	_
18-8	2579-2581	to	_	_	_	_
18-9	2582-2591	determine	_	_	_	_
18-10	2592-2602	resistance	abstract|abstract[134]	giv|new[134]	ana	18-17[0_134]
18-11	2603-2605	or	abstract[134]	new[134]	_	_
18-12	2606-2620	susceptibility	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-13	2621-2623	to	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-14	2624-2632	visceral	abstract[134]|abstract[135]|abstract[136]	new[134]|new[135]|new[136]	coref	20-19[0_136]
18-15	2633-2646	leishmaniasis	abstract[134]|abstract[135]|abstract[136]	new[134]|new[135]|new[136]	_	_
18-16	2647-2650	and	_	_	_	_
18-17	2651-2655	they	abstract	giv	_	_
18-18	2656-2659	are	_	_	_	_
18-19	2660-2666	widely	_	_	_	_
18-20	2667-2679	demonstrated	_	_	_	_
18-21	2680-2682	in	_	_	_	_
18-22	2683-2686	the	abstract[138]	new[138]	_	_
18-23	2687-2697	literature	abstract[138]	new[138]	_	_
18-24	2698-2699	.	_	_	_	_

#Text=Our data support that some peptides were able to induce lymphoproliferation and the production of IFN-γ by T-cells in vitro .
19-1	2700-2703	Our	person|abstract[140]	giv|new[140]	ana	22-1
19-2	2704-2708	data	abstract[140]	new[140]	_	_
19-3	2709-2716	support	_	_	_	_
19-4	2717-2721	that	_	_	_	_
19-5	2722-2726	some	substance[141]	giv[141]	coref	20-31[157_141]
19-6	2727-2735	peptides	substance[141]	giv[141]	_	_
19-7	2736-2740	were	_	_	_	_
19-8	2741-2745	able	_	_	_	_
19-9	2746-2748	to	_	_	_	_
19-10	2749-2755	induce	_	_	_	_
19-11	2756-2775	lymphoproliferation	abstract	new	_	_
19-12	2776-2779	and	_	_	_	_
19-13	2780-2783	the	event[143]	new[143]	_	_
19-14	2784-2794	production	event[143]	new[143]	_	_
19-15	2795-2797	of	event[143]	new[143]	_	_
19-16	2798-2803	IFN-γ	event[143]|object[144]	new[143]|giv[144]	coref	20-26[0_144]
19-17	2804-2806	by	event[143]|object[144]	new[143]|giv[144]	_	_
19-18	2807-2814	T-cells	event[143]|object[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
19-19	2815-2817	in	event[143]|object[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
19-20	2818-2823	vitro	event[143]|object[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
19-21	2824-2825	.	_	_	_	_

#Text=In this regard , in many studies reporting the use of murine model and PBMC from patients with leishmaniasis , the main biomarker analyzed was IFN-γ produced after stimuli with different peptides .
20-1	2826-2828	In	_	_	_	_
20-2	2829-2833	this	abstract[146]	new[146]	_	_
20-3	2834-2840	regard	abstract[146]	new[146]	_	_
20-4	2841-2842	,	_	_	_	_
20-5	2843-2845	in	_	_	_	_
20-6	2846-2850	many	abstract[147]	giv[147]	_	_
20-7	2851-2858	studies	abstract[147]	giv[147]	_	_
20-8	2859-2868	reporting	_	_	_	_
20-9	2869-2872	the	abstract[148]	new[148]	_	_
20-10	2873-2876	use	abstract[148]	new[148]	_	_
20-11	2877-2879	of	abstract[148]	new[148]	_	_
20-12	2880-2886	murine	abstract[148]|animal|abstract[150]	new[148]|new|giv[150]	coref	22-25[176_150]
20-13	2887-2892	model	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
20-14	2893-2896	and	abstract[148]	new[148]	_	_
20-15	2897-2901	PBMC	abstract[148]|abstract[151]	new[148]|new[151]	_	_
20-16	2902-2906	from	abstract[148]|abstract[151]	new[148]|new[151]	_	_
20-17	2907-2915	patients	abstract[148]|abstract[151]|person[152]	new[148]|new[151]|new[152]	_	_
20-18	2916-2920	with	abstract[148]|abstract[151]|person[152]	new[148]|new[151]|new[152]	_	_
20-19	2921-2934	leishmaniasis	abstract[148]|abstract[151]|person[152]|abstract	new[148]|new[151]|new[152]|giv	_	_
20-20	2935-2936	,	_	_	_	_
20-21	2937-2940	the	abstract[154]	new[154]	_	_
20-22	2941-2945	main	abstract[154]	new[154]	_	_
20-23	2946-2955	biomarker	abstract[154]	new[154]	_	_
20-24	2956-2964	analyzed	_	_	_	_
20-25	2965-2968	was	_	_	_	_
20-26	2969-2974	IFN-γ	abstract	giv	coref	23-39
20-27	2975-2983	produced	_	_	_	_
20-28	2984-2989	after	_	_	_	_
20-29	2990-2997	stimuli	abstract[156]	new[156]	_	_
20-30	2998-3002	with	abstract[156]	new[156]	_	_
20-31	3003-3012	different	abstract[156]|substance[157]	new[156]|giv[157]	coref	22-13[0_157]
20-32	3013-3021	peptides	abstract[156]|substance[157]	new[156]|giv[157]	_	_
20-33	3022-3023	.	_	_	_	_

#Text=After the in vitro screening , the reverse antigen screening ( RAS ) was used , a robust methodology that allows the selection of promising targets for the development of vaccines intended to trigger a strong cellular response .
21-1	3024-3029	After	_	_	_	_
21-2	3030-3033	the	abstract[158]	giv[158]	coref	21-7[160_158]
21-3	3034-3036	in	abstract[158]	giv[158]	_	_
21-4	3037-3042	vitro	abstract[158]	giv[158]	_	_
21-5	3043-3052	screening	abstract[158]	giv[158]	_	_
21-6	3053-3054	,	_	_	_	_
21-7	3055-3058	the	abstract[160]	giv[160]	appos	21-12[0_160]
21-8	3059-3066	reverse	abstract[160]	giv[160]	_	_
21-9	3067-3074	antigen	substance|abstract[160]	new|giv[160]	coref	23-4[178_0]
21-10	3075-3084	screening	abstract[160]	giv[160]	_	_
21-11	3085-3086	(	_	_	_	_
21-12	3087-3090	RAS	abstract	giv	_	_
21-13	3091-3092	)	_	_	_	_
21-14	3093-3096	was	_	_	_	_
21-15	3097-3101	used	_	_	_	_
21-16	3102-3103	,	_	_	_	_
21-17	3104-3105	a	abstract[162]	new[162]	_	_
21-18	3106-3112	robust	abstract[162]	new[162]	_	_
21-19	3113-3124	methodology	abstract[162]	new[162]	_	_
21-20	3125-3129	that	_	_	_	_
21-21	3130-3136	allows	_	_	_	_
21-22	3137-3140	the	abstract[163]	new[163]	_	_
21-23	3141-3150	selection	abstract[163]	new[163]	_	_
21-24	3151-3153	of	abstract[163]	new[163]	_	_
21-25	3154-3163	promising	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-26	3164-3171	targets	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-27	3172-3175	for	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-28	3176-3179	the	abstract[163]|abstract[164]|event[165]	new[163]|new[164]|new[165]	_	_
21-29	3180-3191	development	abstract[163]|abstract[164]|event[165]	new[163]|new[164]|new[165]	_	_
21-30	3192-3194	of	abstract[163]|abstract[164]|event[165]	new[163]|new[164]|new[165]	_	_
21-31	3195-3203	vaccines	abstract[163]|abstract[164]|event[165]|substance	new[163]|new[164]|new[165]|giv	coref	26-23
21-32	3204-3212	intended	_	_	_	_
21-33	3213-3215	to	_	_	_	_
21-34	3216-3223	trigger	_	_	_	_
21-35	3224-3225	a	event[167]	giv[167]	coref	22-21[175_167]
21-36	3226-3232	strong	event[167]	giv[167]	_	_
21-37	3233-3241	cellular	event[167]	giv[167]	_	_
21-38	3242-3250	response	event[167]	giv[167]	_	_
21-39	3251-3252	.	_	_	_	_

#Text=Our findings demonstrate that an immunoinformatic approach increases the chance of finding peptides molecules ( epitopes ) which can trigger a cellular response in a naturally and asymptomatic infected model .
22-1	3253-3256	Our	person|abstract[169]	giv|new[169]	ana	24-2
22-2	3257-3265	findings	abstract[169]	new[169]	_	_
22-3	3266-3277	demonstrate	_	_	_	_
22-4	3278-3282	that	_	_	_	_
22-5	3283-3285	an	abstract[170]	giv[170]	_	_
22-6	3286-3302	immunoinformatic	abstract[170]	giv[170]	_	_
22-7	3303-3311	approach	abstract[170]	giv[170]	_	_
22-8	3312-3321	increases	_	_	_	_
22-9	3322-3325	the	abstract[171]	new[171]	_	_
22-10	3326-3332	chance	abstract[171]	new[171]	_	_
22-11	3333-3335	of	_	_	_	_
22-12	3336-3343	finding	_	_	_	_
22-13	3344-3352	peptides	substance|object[173]	giv|new[173]	appos|coref	22-16[0_173]|24-8[189_0]
22-14	3353-3362	molecules	object[173]	new[173]	_	_
22-15	3363-3364	(	_	_	_	_
22-16	3365-3373	epitopes	object	giv	coref	26-18[212_0]
22-17	3374-3375	)	_	_	_	_
22-18	3376-3381	which	_	_	_	_
22-19	3382-3385	can	_	_	_	_
22-20	3386-3393	trigger	_	_	_	_
22-21	3394-3395	a	event[175]	giv[175]	coref	23-7[179_175]
22-22	3396-3404	cellular	event[175]	giv[175]	_	_
22-23	3405-3413	response	event[175]	giv[175]	_	_
22-24	3414-3416	in	event[175]	giv[175]	_	_
22-25	3417-3418	a	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-26	3419-3428	naturally	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-27	3429-3432	and	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-28	3433-3445	asymptomatic	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-29	3446-3454	infected	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-30	3455-3460	model	event[175]|abstract[176]	giv[175]|giv[176]	_	_
22-31	3461-3462	.	_	_	_	_

#Text=The fact that an antigen generates a cellular response classified as type IV or late hypersensitivity implies that this antigen may be able to generate immune memory and trigger a response characterized by important cytokines , such as IFN-γ and TNF-α .
23-1	3463-3466	The	abstract[177]	new[177]	_	_
23-2	3467-3471	fact	abstract[177]	new[177]	_	_
23-3	3472-3476	that	abstract[177]	new[177]	_	_
23-4	3477-3479	an	abstract[177]|substance[178]	new[177]|giv[178]	coref	23-19[180_178]
23-5	3480-3487	antigen	abstract[177]|substance[178]	new[177]|giv[178]	_	_
23-6	3488-3497	generates	abstract[177]	new[177]	_	_
23-7	3498-3499	a	abstract[177]|event[179]	new[177]|giv[179]	coref	23-30[182_179]
23-8	3500-3508	cellular	abstract[177]|event[179]	new[177]|giv[179]	_	_
23-9	3509-3517	response	abstract[177]|event[179]	new[177]|giv[179]	_	_
23-10	3518-3528	classified	_	_	_	_
23-11	3529-3531	as	_	_	_	_
23-12	3532-3536	type	_	_	_	_
23-13	3537-3539	IV	_	_	_	_
23-14	3540-3542	or	_	_	_	_
23-15	3543-3547	late	_	_	_	_
23-16	3548-3564	hypersensitivity	_	_	_	_
23-17	3565-3572	implies	_	_	_	_
23-18	3573-3577	that	_	_	_	_
23-19	3578-3582	this	substance[180]	giv[180]	_	_
23-20	3583-3590	antigen	substance[180]	giv[180]	_	_
23-21	3591-3594	may	_	_	_	_
23-22	3595-3597	be	_	_	_	_
23-23	3598-3602	able	_	_	_	_
23-24	3603-3605	to	_	_	_	_
23-25	3606-3614	generate	_	_	_	_
23-26	3615-3621	immune	abstract[181]	giv[181]	_	_
23-27	3622-3628	memory	abstract[181]	giv[181]	_	_
23-28	3629-3632	and	_	_	_	_
23-29	3633-3640	trigger	_	_	_	_
23-30	3641-3642	a	event[182]	giv[182]	_	_
23-31	3643-3651	response	event[182]	giv[182]	_	_
23-32	3652-3665	characterized	_	_	_	_
23-33	3666-3668	by	_	_	_	_
23-34	3669-3678	important	abstract[183]	giv[183]	_	_
23-35	3679-3688	cytokines	abstract[183]	giv[183]	_	_
23-36	3689-3690	,	abstract[183]	giv[183]	_	_
23-37	3691-3695	such	abstract[183]	giv[183]	_	_
23-38	3696-3698	as	abstract[183]	giv[183]	_	_
23-39	3699-3704	IFN-γ	abstract[183]|abstract	giv[183]|giv	_	_
23-40	3705-3708	and	abstract[183]	giv[183]	_	_
23-41	3709-3714	TNF-α	abstract[183]|abstract	giv[183]|new	_	_
23-42	3715-3716	.	_	_	_	_

#Text=When we analyzed the epitope conservancy of these peptides among the proteome of other Leishmania species , it was observed that peptide PEP17 demonstrated to be the most conserved epitope among various viscerotropic and dermatotropic Leishmania species .
24-1	3717-3721	When	_	_	_	_
24-2	3722-3724	we	person	giv	_	_
24-3	3725-3733	analyzed	_	_	_	_
24-4	3734-3737	the	abstract[188]	new[188]	ana	24-18[0_188]
24-5	3738-3745	epitope	substance|abstract[188]	giv|new[188]	coref	24-27[196_0]
24-6	3746-3757	conservancy	abstract[188]	new[188]	_	_
24-7	3758-3760	of	abstract[188]	new[188]	_	_
24-8	3761-3766	these	abstract[188]|substance[189]	new[188]|giv[189]	coref	25-1[200_189]
24-9	3767-3775	peptides	abstract[188]|substance[189]	new[188]|giv[189]	_	_
24-10	3776-3781	among	_	_	_	_
24-11	3782-3785	the	abstract[190]	new[190]	_	_
24-12	3786-3794	proteome	abstract[190]	new[190]	_	_
24-13	3795-3797	of	abstract[190]	new[190]	_	_
24-14	3798-3803	other	abstract[190]|animal[192]	new[190]|new[192]	coref	24-35[199_192]
24-15	3804-3814	Leishmania	abstract[190]|animal|animal[192]	new[190]|giv|new[192]	_	_
24-16	3815-3822	species	abstract[190]|animal[192]	new[190]|new[192]	_	_
24-17	3823-3824	,	_	_	_	_
24-18	3825-3827	it	abstract	giv	coref	25-9[202_0]
24-19	3828-3831	was	_	_	_	_
24-20	3832-3840	observed	_	_	_	_
24-21	3841-3845	that	_	_	_	_
24-22	3846-3853	peptide	place	new	_	_
24-23	3854-3859	PEP17	substance	new	_	_
24-24	3860-3872	demonstrated	_	_	_	_
24-25	3873-3875	to	_	_	_	_
24-26	3876-3878	be	_	_	_	_
24-27	3879-3882	the	substance[196]	giv[196]	_	_
24-28	3883-3887	most	substance[196]	giv[196]	_	_
24-29	3888-3897	conserved	substance[196]	giv[196]	_	_
24-30	3898-3905	epitope	substance[196]	giv[196]	_	_
24-31	3906-3911	among	substance[196]	giv[196]	_	_
24-32	3912-3919	various	substance[196]|abstract[197]|abstract[198]	giv[196]|new[197]|new[198]	ana	25-23[0_198]
24-33	3920-3933	viscerotropic	substance[196]|abstract[197]|abstract[198]	giv[196]|new[197]|new[198]	_	_
24-34	3934-3937	and	substance[196]|abstract[198]	giv[196]|new[198]	_	_
24-35	3938-3951	dermatotropic	substance[196]|abstract[198]|animal[199]	giv[196]|new[198]|giv[199]	_	_
24-36	3952-3962	Leishmania	substance[196]|abstract[198]|animal[199]	giv[196]|new[198]|giv[199]	_	_
24-37	3963-3970	species	substance[196]|abstract[198]|animal[199]	giv[196]|new[198]|giv[199]	_	_
24-38	3971-3972	.	_	_	_	_

#Text=Immunogenic peptides that show a high degree of conservancy with other parasites may be related to a better protection when compared to those not conserved .
25-1	3973-3984	Immunogenic	substance[200]	giv[200]	coref	26-5[0_200]
25-2	3985-3993	peptides	substance[200]	giv[200]	_	_
25-3	3994-3998	that	_	_	_	_
25-4	3999-4003	show	_	_	_	_
25-5	4004-4005	a	abstract[201]	new[201]	_	_
25-6	4006-4010	high	abstract[201]	new[201]	_	_
25-7	4011-4017	degree	abstract[201]	new[201]	_	_
25-8	4018-4020	of	abstract[201]	new[201]	_	_
25-9	4021-4032	conservancy	abstract[201]|abstract[202]	new[201]|giv[202]	_	_
25-10	4033-4037	with	abstract[201]|abstract[202]	new[201]|giv[202]	_	_
25-11	4038-4043	other	abstract[201]|abstract[202]|animal[203]	new[201]|giv[202]|giv[203]	_	_
25-12	4044-4053	parasites	abstract[201]|abstract[202]|animal[203]	new[201]|giv[202]|giv[203]	_	_
25-13	4054-4057	may	_	_	_	_
25-14	4058-4060	be	_	_	_	_
25-15	4061-4068	related	_	_	_	_
25-16	4069-4071	to	_	_	_	_
25-17	4072-4073	a	abstract[204]	giv[204]	_	_
25-18	4074-4080	better	abstract[204]	giv[204]	_	_
25-19	4081-4091	protection	abstract[204]	giv[204]	_	_
25-20	4092-4096	when	_	_	_	_
25-21	4097-4105	compared	_	_	_	_
25-22	4106-4108	to	_	_	_	_
25-23	4109-4114	those	abstract	giv	_	_
25-24	4115-4118	not	_	_	_	_
25-25	4119-4128	conserved	_	_	_	_
25-26	4129-4130	.	_	_	_	_

#Text=In this way , peptides 17 , 30 , 33 , and 34 may be considered promising epitopes for the design of vaccines against VL .
26-1	4131-4133	In	_	_	_	_
26-2	4134-4138	this	abstract[206]	giv[206]	_	_
26-3	4139-4142	way	abstract[206]	giv[206]	_	_
26-4	4143-4144	,	_	_	_	_
26-5	4145-4153	peptides	substance	giv	_	_
26-6	4154-4156	17	quantity	new	_	_
26-7	4157-4158	,	_	_	_	_
26-8	4159-4161	30	time[209]	new[209]	_	_
26-9	4162-4163	,	time[209]	new[209]	_	_
26-10	4164-4166	33	time[209]|quantity	new[209]|new	_	_
26-11	4167-4168	,	_	_	_	_
26-12	4169-4172	and	_	_	_	_
26-13	4173-4175	34	quantity	new	_	_
26-14	4176-4179	may	_	_	_	_
26-15	4180-4182	be	_	_	_	_
26-16	4183-4193	considered	_	_	_	_
26-17	4194-4203	promising	_	_	_	_
26-18	4204-4212	epitopes	object[212]	giv[212]	_	_
26-19	4213-4216	for	object[212]	giv[212]	_	_
26-20	4217-4220	the	object[212]|abstract[213]	giv[212]|new[213]	_	_
26-21	4221-4227	design	object[212]|abstract[213]	giv[212]|new[213]	_	_
26-22	4228-4230	of	object[212]|abstract[213]	giv[212]|new[213]	_	_
26-23	4231-4239	vaccines	object[212]|abstract[213]|substance	giv[212]|new[213]|giv	_	_
26-24	4240-4247	against	object[212]|abstract[213]	giv[212]|new[213]	_	_
26-25	4248-4250	VL	object[212]|abstract[213]|abstract	giv[212]|new[213]|new	_	_
26-26	4251-4252	.	_	_	_	_
